Pharmacological management of appetite expression in obesity
- 16 March 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 6 (5) , 255-269
Abstract
Antiobesity drugs are chosen for their ability to suppress food intake or body weight, with little regard for the psychological factors that influence consumption and weight gain. This Review argues that selective pharmacological targeting of specific emotional and motivational processes that govern appetite and eating may improve outcomes for weight reduction and improved self-control over consumption. For obese individuals, successful weight loss and maintenance are notoriously difficult. Traditional drug development fails to exploit knowledge of the psychological factors that crucially influence appetite, concentrating instead on restrictive criteria of intake and weight reduction, allied to a mechanistic view of energy regulation. Drugs are under development that may produce beneficial changes in appetite expression in the obese. These currently include glucagon-like peptide-1 analogs such as liraglutide, an amylin analog davalintide, the 5-HT2C receptor agonist lorcaserin, the monoamine re-uptake inhibitor tesofensine, and a number of combination therapies such as pramlintide and metreleptin, bupropion and naltrexone, phentermine and topiramate, and bupropion and zonisamide. However, the effects of these treatments on eating behavior remain poorly characterized. Obesity is typically a consequence of overconsumption driven by an individual's natural sensitivity to food stimuli and the pleasure derived from eating. Intuitively, these processes should be effective targets for pharmacotherapy, and behavioral analysis can identify drugs that selectively affect desire to eat, enjoyment of eating, satiation or postmeal satiety. Rational interventions designed specifically to modulate these processes could limit the normally aversive consequences of caloric restriction and maximize an individual's capacity to successfully gain control over their appetite.Keywords
This publication has 185 references indexed in Scilit:
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity PharmacotherapyObesity, 2009
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical resultsBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Widespread reward-system activation in obese women in response to pictures of high-calorie foodsNeuroImage, 2008
- Prevalence and correlates of binge eating disorder in a community sampleComprehensive Psychiatry, 2007
- Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsCell Metabolism, 2006
- Short-term effects of sibutramine (ReductilTM) on appetite and eating behaviour and the long-term therapeutic outcomeInternational Journal of Obesity, 2003
- Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin DeficiencyNew England Journal of Medicine, 1999
- Original Articles Sibutramine Reduces Food Intake in Non‐Dieting Women with ObesityObesity Research, 1998
- Biological and psychological correlates of intermittent dieting behavior in young women. A model for bulimia nervosaPhysiology & Behavior, 1996
- The Association of Body Weight, Dietary Intake, and Energy Expenditure with Dietary Restraint and DisinhibitionObesity Research, 1995